Drug intelligence / Profile preview

LEO 130852A

Development stage: Phase 1
Lead developer: LEO Pharma
Modality: Small Molecules
Administration: Topical

Overview

LEO 130852A is a topically administered investigational agent being developed by LEO Pharma for the treatment of steroid-induced skin atrophy. The drug is currently in phase I clinical trials, where it is being evaluated for its ability to maintain skin thickness and reduce the atrophic effects caused by topical corticosteroid use. The precise mechanism of action has not been disclosed, but its development targets prevention or mitigation of skin thinning associated with prolonged steroid therapy.

Beyond the preview

Go deeper on LEO 130852A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LEO 130852A.

Explore the full profile